Ensign Peak Advisors’s ALX Oncology ALXO Stock Holding History

Ensign Peak Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.68M	Sell	810,297 -140,253	-15%	-$251K	﹤0.01%	775
2026 Q1	$1.91M	Buy	+950,550	New	+$1.81M	﹤0.01%	719
2022 Q3	–	Sell	-1,350	Closed	-$11K	–	2311
2022 Q2	$11K	Sell	1,350 -126,082	-99%	-$1.37M	﹤0.01%	2143
2022 Q1	$2.15M	Hold	127,432	–	–	﹤0.01%	852
2021 Q4	$2.74M	Sell	127,432 -218,052	-63%	-$9.41M	0.01%	849
2021 Q3	$25.5M	Sell	345,484 -31,381	-8%	-$2.09M	0.05%	275
2021 Q2	$20.6M	Buy	376,865 +40,566	+12%	+$2.43M	0.04%	313
2021 Q1	$24.8M	Buy	336,299 +309,255	+1,144%	+$24.3M	0.05%	276
2020 Q4	$2.33M	Buy	+27,044	New	+$1.63M	0.01%	972

Other funds holding ALXO

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Ensign Peak Advisors's ALXO Position: Q2 2026 in Review

Ensign Peak Advisors reduced its ALX Oncology (ALXO) stake by 15% in Q2 2026, selling an estimated $251K and leaving 810,297 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #775.

Ensign Peak Advisors first reported a position in ALXO in Q4 2020 and has held it in 9 quarters since. The position peaked at $25.5M in Q3 2021. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

Ensign Peak Advisors held 810,297 shares of ALX Oncology worth $1.68M as of Q2 2026.
Ensign Peak Advisors sold 140,253 ALX Oncology shares in Q2 2026, an estimated $251K.
ALX Oncology made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #775 holding.
Ensign Peak Advisors first reported a position in ALX Oncology in Q4 2020 and has held it in 9 quarters since.
Ensign Peak Advisors's ALX Oncology position peaked at $25.5M in Q3 2021.
94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.